March 18 (Reuters) - The U.S. Food and Drug Administration on Wednesday issued a draft guidance to help companies reduce animal studies of experimental drugs and adopt newer methods, such as computer ...

The Trump administration is redoubling its efforts to phase out animal testing in drug development and seeking to develop new ...

The guidance clarifies what sponsors should consider when putting together an application for the validation of a NAM ...

New draft guidance from the FDA is urging pharma companies to accelerate efforts to transition from animal testing to ...

US FDA releases draft guidance on alternatives to animal testing in drug development: Silver Spring, Maryland Friday, March 20, 2026, 10:00 Hrs [IST] The US Food and Drug Administ ...

Officials with the FDA have released a draft guidance that aims to help drug developers validate new approach methodologies (NAMs) that can be used in place of animal testing. Based on human-centric ...

In April 2025, the FDA announced plans to shift biomedical research for monoclonal antibodies and other medications away from animal testing toward new approaches. One year later, much speculation ...

Health authorities in the U.S. are continuing their move away from animal testing in drug development, with the FDA signaling an openness to new approaches that haven’t been validated and the National ...

The FDA has released a draft guidance outlining how drug developers can validate new approach methodologies (NAMs) as alternatives to animal testing in preclinical drug development. The guidance, ...

Animal studies often fail to predict human tissue responses to new drugs or newly developed therapies. Besides generating tremendous costs for clinical studies, it also raises significant ethical ...

Last November, the UK government announced a bold plan to phase out animal testing in some areas of research. Animal tests for skin irritation are scheduled for elimination this year, and some studies ...